Clinical trials: Low-Density-Lipoprotein-cholesterol Level
HDL Cholesterol
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)
Summary: Background: There is a lot of interest in the function and role of HDL to prevent and mitigate atherosclerosis in patients who are at or near LDLc targets.
- Trial name
- NCT00736463
- Testing
- Simvastatin, Atorvastatin 80 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Oregon Health and Science University
Hypercholesterolemia, Dyslipidaemia
Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)
The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in South Asian subjects with hypercholesterolemia.
- Trial name
- IRIS (NCT00654225)
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 2,340 people
- Sponsor
- AstraZeneca
Heterozygous Familial Hypercholesterolaemia
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or…
- Trial name
- AZURE-HeFH (NCT07000136)
- Testing
- AZD0780
- Where
- 133 sites in United States, Argentina and 22 more
- Volunteers
- 473 people
- Sponsor
- AstraZeneca
Healthy
Effect of Bergamot Juice on LDL Cholesterol Level in Healthy Subjects
A single-centre, randomized (1:1), open label, controlled study to assess the lipid-lowering effect at 12 weeks of 400 cc/die bergamot juice consumption compared to free diet in healthy subjects
- Trial name
- NCT05589636
- Testing
- Bergamot Juice
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Hypercholesterolemia
The Effects of Lowering Low-density Lipoprotein Cholesterol Levels to New Targets on Cardiovascular Complications in Peritoneal Dialysis Patients
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in dialysis patients. Although significant improvements have been made in the management of CVD in the general population, it is not known whether these…
- Trial name
- NCT00999453
- Testing
- LDL-cholesterol
- Where
- 2 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Clinical Research Center for End Stage Renal Disease, Korea
Hypercholesterolemia
Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects
Study AFF012 is a single blind, single-center, randomized, placebo-controlled, parallel group, phase I clinical trial of repeated administration by subcutaneous injection of a single dose of one of two different proprotein…
- Trial name
- AFF012 (NCT02508896)
- Testing
- AFFITOPE® AT04A+adjuvant, AFFITOPE® AT06A+adjuvant, Adjuvant without active component
- Where
- Austria
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Affiris AG
Cardiovascular Disease, Diabetes
The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study
The purpose of this study is to test the effects of natural vs. man-made trans fatty acids (trans fats) on blood cholesterol.
- Conditions
- Cardiovascular Disease, Diabetes, Dyslipidemia
- Trial name
- NCT00535886
- Testing
- Man-made Trans FA, Natural Trans FA, Oleic Acid
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Blood Pressure, Low Density Lipoprotein Cholesterol Level
Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol
The purpose of this study is to evaluate the benefit and tolerability of IQP-AS-118 on the systolic and diastolic blood pressure (BP) and to explore the effects on parameters of lipid metabolism in subjects with elevated BP and…
- Trial name
- NCT02871362
- Testing
- IQP-AS-118
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Hypercholesterolaemia
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood.
- Trial name
- NCT07619131
- Testing
- Laroprovstat, Rosuvastatin 1, Rosuvastatin 2
- Where
- 152 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Dyslipidemia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination…
- Trial name
- NCT05787002
- Testing
- AZD0780, Rosuvastatin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dyslipidemia
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia.
- Trial name
- PURSUIT (NCT06173570)
- Testing
- AZD0780
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 428 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Coronary Disease
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
- Trial name
- NCT00092612
- Testing
- MK0653, ezetimibe
- Volunteers
- 372 people
- Sponsor
- Organon and Co
Hyperlipidemia, Hypercholesterolemia
Patient and Provider Assessment of Lipid Management Registry
The purpose of the Patient and Provider Assessment of Lipid Management Registry (PALM) is to gain a better understanding of physicians' cholesterol medication prescribing practices, patient and physician attitudes and beliefs…
- Conditions
- Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes
- Trial name
- PALM (NCT02341664)
- Where
- 14 sites in United States
- Volunteers
- 7,658 people
- Sponsor
- Duke University
Atherosclerotic Cardiovascular Disease
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory…
- Trial name
- AZD0780-ABPM (NCT06692764)
- Testing
- AZD0780
- Where
- 26 sites in United States
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Hypertension, Dyslipidemias
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive…
- Trial name
- NCT05660135
- Testing
- Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
- Where
- South Korea
- Volunteers
- 4,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Coronary Artery Diseasse
Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease
To compare clinical safety \& efficacy of fixed-high potent statin therapy (according to 2013 ACC/AHA guideline) vs. targeted LDL-C goal statin therapy (LDL<70mg/dL) for secondary prevention.
- Trial name
- LODESTAR (NCT02579499)
- Testing
- fixed high potent statin therapy, targeted LDL-C goal statin
- Where
- South Korea
- Volunteers
- 4,400 people
- Sponsor
- Yonsei University
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST 2 (NCT00442325)
- Testing
- Atorvastatin (Lipitor)
- Where
- 32 sites in Greece, Hungary and 6 more
- Volunteers
- 595 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
- Trial name
- CLEAR Path 1 (NCT05694260)
- Testing
- Bempedoic acid
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 31 people
- Sponsor
- Esperion Therapeutics, Inc.
Elevated LDL Cholesterol
A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol
This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril) as compared to the effect on LDL cholesterol of…
- Trial name
- NCT01004705
- Testing
- Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ferrer Internacional S.A.
Cardiovascular Disease
Effects of Almonds on Cardiovascular Risk Factors
The purpose of this research is to build the evidence base for approval of FDA health claims related to almonds and cardiovascular disease.
- Trial name
- ALD (NCT01101230)
- Testing
- Almonds
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Penn State University